報告人🧍🏻：張傑，資深研究員

The Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark

BioInnovation Institute, Denmark

報告時間：2022年10月5日，15：00-16：00

報告地點：騰訊會議

https://meeting.tencent.com/dm/42eFz51r56rK

報告人簡介🧏🏿‍♂️：

2011年於瑞典查爾姆斯理工大學獲得系統生物學博士學位，師從Jens Nielsen院士，主要研究釀酒酵母中碳源和能量代謝網絡的調控。隨後在美國麻省理工EON4進行博士後研究🪲，主要課題為癌細胞的中心代謝途徑及腫瘤分子標誌物。2014年開始作為研究員加入丹麥技術大學(Technical University of Denmark)諾和諾德基金會生物可持續性研究中心(Novo Nordisk Foundation Center for Biosustainability)以及丹麥生物創新研究所(BioInnovation Institute)🤽，主導酵母的合成生物學元器件開發，轉錄因子類生物傳感器的設計及其在植物天然產物代謝工程領域的應用。在Nature, Nat Chem Biol, Nat Comm, Nucleic Acids Res, Mol Syst Biol, Metab Eng, ACS Synth Biol 等雜誌發表高水平學術論文20余篇。

報告摘要🖕🏼：

Monoterpene indole alkaloids (MIAs) are a diverse family of complex plant secondary metabolites with many medicinal properties, including anti-cancer, anti-hypertensive, anti-malarial, anti-addiction, analgesic, etc. As MIAs are difficult to chemically synthesize, their supply is exclusively dependent on plant extraction, which is vulnerable to factors such as plant diseases, natural disasters, pandemics and interruptions in global logistics. For example, a shortage of the chemotherapeutics vinblastine and vincristine has interrupted the cancer treatments of many children patients, because no alternative medicines are available. To establish an alternative source of these medicinal alkaloids independent of their natural plant producers, we engineered the baker’s yeast S. cerevisiae to produce strictosidine, a common precursor of all MIAs. We also demonstrate the biosynthesis of vindoline and catharanthine using yeast fermentation, and chemically coupled them to produce the anti-cancer drug vinblastine. In principle, similarly engineered yeast strains could produce more than 3,000 natural MIAs and their unnatural analogues.